Alkaline phosphatase

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Targeting HIV-1 Env gp140 antibodiesPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
TemelimabGNN-001; GENHP-01; GNbAC-1Phase 2 ClinicalGeneuro SaMultiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome
Details
PGDM-1400PGDM-1400; PGDM1400LSPhase 2 ClinicalInternational Aids Vaccine InitiativeHIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity
Details
VIS-513VIS-513; Ab-513Phase 1 ClinicalOtsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra IncDengue
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
TecovirimatSIGA-246; ST-246ApprovedSiga Technologies IncTpoxxUnited StatesSmallpoxSiga Technologies Inc2018-07-13Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland